3.91
price up icon0.77%   0.03
after-market Handel nachbörslich: 3.74 -0.17 -4.35%
loading

X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten

pulisher
03:25 AM

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

03:25 AM
pulisher
08:00 AM

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Markets Financial Content

08:00 AM
pulisher
Dec 11, 2025

X4 PharmaSeizing Rare Opportunities, Not Acting On A Whim - RTTNews

Dec 11, 2025
pulisher
Dec 10, 2025

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Dec 10, 2025
pulisher
Dec 10, 2025

Does X4 Pharmaceuticals Inc (XFOR) offer a good opportunity for investors? - setenews.com

Dec 10, 2025
pulisher
Dec 08, 2025

X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Pale Fire Capital SE - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring Moves - Yahoo Finance

Dec 08, 2025
pulisher
Dec 06, 2025

Blood pressure drug recalled for possible cross-contamination - USA Today

Dec 06, 2025
pulisher
Dec 05, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 05, 2025
pulisher
Dec 05, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Dec 05, 2025
pulisher
Dec 05, 2025

XFOR Stock Update: Stifel Raises Target Price to $10.00 | XFOR S - GuruFocus

Dec 05, 2025
pulisher
Dec 05, 2025

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness - BioSpace

Dec 05, 2025
pulisher
Dec 04, 2025

Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) - Yahoo Finance

Dec 04, 2025
pulisher
Dec 04, 2025

How X4 Pharmaceuticals Inc. stock reacts to oil prices2025 Technical Overview & Stepwise Swing Trade Plans - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Is X4 Pharmaceuticals Inc. (48Q0) stock a safe buy pre earningsFed Meeting & Intraday High Probability Alerts - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Dec 03, 2025
pulisher
Dec 03, 2025

Take off with X4 Pharmaceuticals Inc (XFOR): Get ready for trading - Setenews

Dec 03, 2025
pulisher
Dec 03, 2025

Why pension funds invest in X4 Pharmaceuticals Inc. (48Q0) stockWeekly Earnings Recap & Weekly Breakout Opportunity Watchlist - Newser

Dec 03, 2025
pulisher
Dec 03, 2025

Is X4 Pharmaceuticals Inc. stock positioned for long term growthJuly 2025 Gainers & Comprehensive Market Scan Reports - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

Will X4 Pharmaceuticals Inc. (48Q0) stock profit from AI boomTrade Ideas & Fast Exit and Entry Strategy Plans - Newser

Dec 02, 2025
pulisher
Dec 01, 2025

An analyst sees good growth prospects for Nano X Imaging Ltd (NNOX) - Setenews

Dec 01, 2025
pulisher
Dec 01, 2025

X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR) - Seeking Alpha

Dec 01, 2025
pulisher
Dec 01, 2025

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome - Yahoo Finance

Dec 01, 2025
pulisher
Dec 01, 2025

X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Wall Street Zen - Defense World

Dec 01, 2025
pulisher
Dec 01, 2025

Layoff Tracker: Adare Shuts Down Philadelphia Plant, Leaving 137 Jobless - BioSpace

Dec 01, 2025
pulisher
Nov 28, 2025

SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - Investing News Network

Nov 28, 2025
pulisher
Nov 28, 2025

Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Momentum Check & Free High Accuracy Swing Entry Alerts - moha.gov.vn

Nov 28, 2025
pulisher
Nov 28, 2025

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - Morningstar

Nov 28, 2025
pulisher
Nov 27, 2025

Can X4 Pharmaceuticals Inc. stock deliver sustainable ROE2025 Macro Impact & Low Volatility Stock Recommendations - moha.gov.vn

Nov 27, 2025
pulisher
Nov 26, 2025

Earnings Report: Can X4 Pharmaceuticals Inc. stock sustain institutional interestTrade Risk Summary & AI Powered Buy and Sell Recommendations - moha.gov.vn

Nov 26, 2025
pulisher
Nov 25, 2025

Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 31% - simplywall.st

Nov 25, 2025
pulisher
Nov 24, 2025

Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing - Yahoo Finance

Nov 24, 2025
pulisher
Nov 24, 2025

Head-To-Head Contrast: Werewolf Therapeutics (NASDAQ:HOWL) versus X4 Pharmaceuticals (NASDAQ:XFOR) - Defense World

Nov 24, 2025
pulisher
Nov 23, 2025

X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded to Hold at Wall Street Zen - Defense World

Nov 23, 2025
pulisher
Nov 21, 2025

Is X4 Pharmaceuticals Inc. stock positioned for digital transformation2025 Price Action Summary & Comprehensive Market Scan Insights - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Why X4 Pharmaceuticals Inc. (48Q0) stock remains top ratedWeekly Trend Report & AI Enhanced Trading Alerts - newser.com

Nov 21, 2025
pulisher
Nov 19, 2025

Will X4 Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Short Interest & Growth Oriented Trading Recommendations - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

X4 Pharmaceuticals Inc (XFOR) Performance and Fundamentals Dashboard tells a completely different story - Setenews

Nov 19, 2025
pulisher
Nov 19, 2025

How to build a dashboard for X4 Pharmaceuticals Inc. stockWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

WHIM Syndrome Research Analysis Report 2025-2035: Market Advances as X4 Pharmaceuticals Leads Innovation in CXCR4-Targeted Therapies - Yahoo Finance

Nov 18, 2025
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
Kapitalisierung:     |  Volumen (24h):